Table 1.
Characteristics | Cancer Patients N (%) |
---|---|
N = 878 | |
Sex | |
Male | 275 (31.3) |
Female | 603 (68.7) |
Age | |
Median (Range) | 62 (18–91) |
18–49 | 171 (19.5) |
50–64 | 334 (38.0) |
65–74 | 264 (30.1) |
≥75 | 109 (12.4) |
BMI | |
Median (Range) | 25 (17–43) |
Obesity (BMI ≥ 30) | 141 (19.9) |
missing data | 170 |
Tobacco smoking status | |
Non-smoker | 299 (47.8) |
Former smoker | 228 (36.4) |
Current smoker | 99 (15.8) |
missing data | 252 |
Public-facing role 1 | |
No | 283 (58.1) |
Yes | 204 (41.9) |
missing data | 391 |
No. of Comorbidities 2 | |
≥1 | 330 (40.7) |
missing data | 67 |
No. of Comedications 3 | |
≥1 | 235 (29.0) |
missing data | 68 |
Centers of inclusion | |
Nantes | 201 (22.9) |
Angers | 238 (27.1) |
Clermont-Ferrand | 159 (18.1) |
Nancy | 280 (31.9) |
Symptoms 4 | |
Symptomatic | 282 (32.1) |
Asymptomatic | 596 (67.9) |
COVID-19 tests 5 | |
Any positive test | 70 (8.0) |
Positive serological test | 59 (6.7) |
Positive RT-PCR test | 26 (3.0) |
1 Public-facing role: The question asked was: “Does your job involve contact with the public?”; 2 Comorbidities included: hypertension, diabetes, chronic respiratory failure, chronic kidney failure, chronic heart failure, weight loss, autoimmune disease, surgery under general anesthesia in the last 12 months; 3 Comedications included corticosteroids, Nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressive drugs, and immunomodulatory drugs; 4 Symptomatic: having at least one COVID-19 symptom; Asymptomatic: having no COVID-19 symptoms; 5 Positive test results: Any positive result from M0 to M3 follow-ups.